{"id":"hydroxymethylnicotinamide","rwe":[],"tags":[{"label":"hydroxymethylnicotinamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"bilamid","offLabel":[],"synonyms":["n-hydroxymethylnicotinamide","3-Pyridinecarboxylic acid hydroxymethylamide","bilamid","bilizorin","bilocid","biloide","biobilan","cholamid","cholamide","coloton","felosan","isochol","nicodin","nicodine","nicometamide","nikodin","nikomethamide","hydroxymethylnicotinamide"],"timeline":[],"approvals":[],"brandName":"Bilamid","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"hydroxymethylnicotinamide","explanation":"Think of it like a key that unlocks a specific process in the body. By changing the way nicotinamide works, Bilamid can help to treat certain conditions. This process is complex and involves many different molecules and cells, but essentially, Bilamid helps to regulate the way the body uses energy.","oneSentence":"Bilamid works by modifying the activity of nicotinamide, a form of vitamin B3, to produce a therapeutic effect.","technicalDetail":"Bilamid acts as a prodrug of nicotinamide, which is then converted into its active form, NAD+, a crucial coenzyme involved in various cellular processes, including energy metabolism and DNA repair."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1905","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=hydroxymethylnicotinamide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:00:51.433003","biosimilars":[],"competitors":[],"genericName":"hydroxymethylnicotinamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1N1YGM997E","CHEBI":"CHEBI:134775","UMLSCUI":"C0117437","ChEMBL_ID":"CHEMBL92024","PUBCHEM_CID":"77116","MESH_SUPPLEMENTAL_RECORD_UI":"C004962"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Bilamid, also known as hydroxymethylnicotinamide, is a small molecule drug of the hydroxymethylnicotinamide class. Unfortunately, there is limited information available on this compound, including its target, approved indications, and commercial status. As a result, it is difficult to provide a comprehensive summary of its use and safety profile. Further research is needed to determine the efficacy and safety of Bilamid in clinical settings. Its development and current ownership are also unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}